Skip to main content

Daniel Kelly Benjamin, MD, PhD

Kiser-Arena Distinguished Professor
Professor of Pediatrics
Member in the Duke Clinical Research Institute
Campus mail: 7044 Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27710
Phone: (919) 668-7081

Dr. Danny Benjamin is the Principal Investigator and Chair of the National Institute of Child Health and Human Development’s Pediatric Trials Network. The Network is responsible for designing and leading clinical trials of off-patent medicines in children of all ages across all therapeutic areas. The team has established, or is actively studying, the correct dosing and safety of more than 70 of the most commonly used medicines in children. Each of these trials is conducted under an Investigational New Drug (IND) application with guidance from the Food and Drug Administration for labeling.

The Pediatric Trials Network has directly impacted the healthcare of over 90% of American children.

Signature programs of the Network include clinical trials in premature, term infants, breast feeding mothers, and obese children. Over the past 10 years, Danny’s group has enrolled more premature infants, at more sites, in more clinical trials of off-patent anti-infectives under an IND than all other academic medical centers, pharmaceutical companies, and government agencies in the world, combined.

Danny is recognized by the National Institutes of Health as a premiere mentor and educator. His research program serves as a platform to train students and early career investigators. Danny’s group has a clinical research summer program for high school and college students targeting under-represented minority students, and he is the primary mentor for medical students, residents, subspecialty fellows, and multiple junior faculty. He has been the primary or secondary mentor for 10 faculty who have received career development awards and who have then gone on to secure their own funding.

Danny's service to the community is expressed through his passion for coaching baseball. He has coached over 500 recreation league, travel league, and scholastic baseball games and he is the head coach of Smith Middle School, the 5-year reigning southern conference champions. Danny and his wife own a charitable non-profit that provides athletic and fitness opportunities for disadvantaged school-aged boys and girls.

Education and Training

  • Fellow, Pediatric Infectious Diseases, Pediatrics, Duke University, 1998 - 2001
  • Resident, Pediatrics, Children's Hospital, 1995 - 1998
  • Ph.D., University of North Carolina - Chapel Hill, 2003
  • M.P.H., University of North Carolina - Chapel Hill, 2001
  • M.D., University of Virginia, 1995

Selected Grants and Awards

Publications

Lloyd, Jessica C., Christoph P. Hornik, Daniel K. Benjamin, Reese H. Clark, Jonathan C. Routh, and P Brian Smith. “Incidence of Breakthrough Urinary Tract Infection in Hospitalized Infants Receiving Antibiotic Prophylaxis.” Clin Pediatr (Phila) 56, no. 1 (January 2017): 65–70. https://doi.org/10.1177/0009922816638664.

Full Text

Smith, P Brian, Daniel K. Benjamin, and Ann M. Reed. “The Role of a Division of Quantitative Sciences Division in Enhancing Academic Productivity of a Department of Pediatrics.” J Pediatr 180 (January 2017): 4–5. https://doi.org/10.1016/j.jpeds.2016.09.042.

Full Text

Hornik, Christoph P., Daniel K. Benjamin, P Brian Smith, Michael J. Pencina, Adriana H. Tremoulet, Edmund V. Capparelli, Jessica E. Ericson, Reese H. Clark, Michael Cohen-Wolkowiez, and Michael Best Pharmaceuticals for Children Act—Pediatric Trials Network. “Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates.” J Pediatr 178 (November 2016): 125-129.e1. https://doi.org/10.1016/j.jpeds.2016.07.011.

Full Text

Autmizguine, Julie, Christoph P. Hornik, Daniel K. Benjamin, Kim L. R. Brouwer, Susan R. Hupp, Michael Cohen-Wolkowiez, and Kevin M. Watt. “Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.” Pediatr Infect Dis J 35, no. 11 (November 2016): 1204–10. https://doi.org/10.1097/INF.0000000000001268.

Full Text

Zimmerman, Kanecia, Martin Putera, Christoph P. Hornik, P. Brian Smith, Daniel K. Benjamin, Yeruk Mulugeta, Gilbert J. Burckart, Michael Cohen-Wolkowiez, and Daniel Gonzalez. “Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval.” Clin Ther 38, no. 9 (September 2016): 1995–2005. https://doi.org/10.1016/j.clinthera.2016.06.003.

Full Text

Ericson, Jessica E., David A. Kaufman, Stephen D. Kicklighter, Jatinder Bhatia, Daniela Testoni, Jamie Gao, P Brian Smith, et al. “Fluconazole Prophylaxis for the Prevention of Candidiasis in Premature Infants: A Meta-analysis Using Patient-level Data.” Clin Infect Dis 63, no. 5 (September 1, 2016): 604–10. https://doi.org/10.1093/cid/ciw363.

Full Text

Folgori, Laura, Julia Bielicki, Beatriz Ruiz, Mark A. Turner, John S. Bradley, Daniel K. Benjamin, Theoklis E. Zaoutis, et al. “Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review.” Lancet Infect Dis 16, no. 9 (September 2016): e178–89. https://doi.org/10.1016/S1473-3099(16)00069-4.

Full Text

Momper, Jeremiah D., Edmund V. Capparelli, Kelly C. Wade, Anand Kantak, Ramasubbareddy Dhanireddy, James J. Cummings, Jonathan H. Nedrelow, et al. “Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams.” Antimicrob Agents Chemother 60, no. 9 (September 2016): 5539–45. https://doi.org/10.1128/AAC.00963-16.

Full Text

Romaine, Andrew, Daniel Ye, Zachary Ao, Francia Fang, Octavious Johnson, Taylor Blake, Daniel K. Benjamin, et al. “Safety of histamine-2 receptor blockers in hospitalized VLBW infants.” Early Hum Dev 99 (August 2016): 27–30. https://doi.org/10.1016/j.earlhumdev.2016.05.010.

Full Text

Gonzalez, Daniel, Paula Delmore, Barry T. Bloom, C Michael Cotten, Brenda B. Poindexter, Elisabeth McGowan, Karen Shattuck, et al. “Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants.” Antimicrob Agents Chemother 60, no. 5 (May 2016): 2888–94. https://doi.org/10.1128/AAC.03086-15.

Full Text

Pages